ON012380

Known as: ON 012380, ON-012380 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2009
012320062009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
the disparities are unknown but may involve several factors, including the assays and cell models used to define the specificity… (More)
  • figure 3
  • table 1
Is this relevant?
Review
2009
Review
2009
At present, there are no compounds in clinical development in the field of chronic myeloid leukemia (CML) or Philadelphia… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2007
Review
2007
Chronic myeloid leukemia (CML) was the first human malignant disease to be linked to a single, acquired genetic abnormality… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2006
Review
2006
Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia… (More)
Is this relevant?
Review
2006
Review
2006
Imatinib mesylate, Abl tyrosine kinase inhibitor, has improved the treatment of Bcr-Abl-positive leukemia such as chronic myeloid… (More)
Is this relevant?
Review
2006
Review
2006
Imatinib mesylate (Gleevec) was developed as the first molecularly targeted therapy that specifically inhibits the BCR-ABL… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?